A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 26 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2018 Planned End Date changed from 2 Apr 2020 to 19 Jun 2019.
- 30 Mar 2018 Planned primary completion date changed from 2 Apr 2020 to 19 Jun 2019.